

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 August 2010 (26.08.2010)

PCT

(10) International Publication Number
WO 2010/095048 A2

- (51) **International Patent Classification:** Not classified
- (21) **International Application Number:** PCT/IB2010/000589
- (22) **International Filing Date:** 22 February 2010 (22.02.2010)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:** 61/154,369 21 February 2009 (21.02.2009) US
- (71) **Applicant (for all designated States except US):** SOFRADIM PRODUCTION [FR/FR]; 116 avenue du Formans, F-01600 Trevoux (FR).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** LADET, Sébastien [FR/FR]; 129 avenue Thiers, F-69006 Lyon (FR). GRAVAGNA, Philippe [FR/FR]; 23 Grande rue, F-69540 Irigny (FR).
- (74) **Agent:** CABINET GERMAIN & MAUREAU; BP 6153, F-69466 Lyon Cedex 06 (FR).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report (Rule 48.2(g))



WO 2010/095048 A2

(54) **Title:** FUNCTIONALIZED ADHESIVE MEDICAL GEL

(57) **Abstract:** The present invention relates to a kit comprising: - a medical gel having a plurality of reactive members of a specific binding pair adapted to be attached on a surface of the gel; and - a container containing a mixture including complementary reactive members of the specific binding pair, the complementary reactive members having a functionality that will adhere them to biological tissue upon contact. The invention further relates to a bioadherent substrate including such a medical gel and to a method of forming such a medical gel.

FUNCTIONALIZED ADHESIVE MEDICAL GEL

5

The present invention relates to a kit comprising a medical gel and a container including a mixture intended to make the medical gel adhere to a biological tissue. The invention also relates to a bioadherent substrate comprising such a medical gel and to a method of forming such a medical gel. The present disclosure relates to adhesive modalities for repair of biological tissues.

Medical adhesives or "tissue glue" have much potential in medicine. Certain adhesive materials are known which may be used to adhere tissue such as skin. For example, cyanoacrylate adhesives been used to bond tissue. In addition to cyanoacrylate adhesives, other types of materials have been reported to adhere to skin. For example, U.S. Pat. No. 4,839,345 to Doi et al. reports a hydrated crosslinked protein adhesive gel that is used as a cataplasm or cosmetic mask that will externally adhere to skin but can be removed and then re-adhered to the skin. Other crosslinked protein hydrogels have been reported to serve as a proteinaceous substrate to deliver therapeutic agents such as enzymes or drugs through skin or mucous membranes. Still other materials have been used as hemostatic agents to stop or prevent bleeding. For example, mixtures of fibrinogen and thrombin such as TISSEEL[®] sealant available from Baxter International, Inc. or BERIPLAST-P[®] hemostatic agent or sealant available from Aventis Behring, have been used in vascular surgery to seal tissue such as blood vessels and thus prevent blood leakage. However, surgical adhesives can tend to form a physical barrier between the

item or items being attached to biological tissue, thus interfering with tissue ingrowth into the item when ingrowth is desired.

The use of medical gels such as hydrogels can be advantageous due to the physico-chemical properties of the hydrogels. Hydrogels typically have excellent
5 compatibility with human and animal tissue. Physically cross linked hydrogels can withstand attack by body fluids, blood, urine and other bodily secretions without significant damage. Many are typically non-adherent to tissue, do not have an affinity for binding to proteins and do not have cell adsorption. Hydrogels are typically non-thrombogenic. These characteristics have been utilized, e.g., for prevention of adhesions
10 after surgery. The ability of hydrogels to act as bulking agents has been utilized in connection with treatment of gastroesophageal reflux disease (GERD), urinary incontinence, fecal incontinence and sterilization of mammals. Hydrogels have also been used to create a matrix in the treatment of damaged cartilage.

Click chemistry is a popular term for reliable reactions that make it possible for
15 certain chemical building blocks to “click” together and form an irreversible linkage. See, e.g., US Pub. No. 2005/0222427. In the case of azide-alkyne click chemistry, the reactions may be catalyzed or uncatalyzed. For example, copper -free click chemistry was recently developed by Bertozzi and colleagues using difluorinated cyclooctyne or DIFO, that reacts with azides rapidly at physiological temperatures without the need for a toxic
20 catalyst. See, e.g., Baskin et al., Copper Free Click Chemistry for Dynamic In Vivo Imaging, PNAS, vol. 104, no. 43, 16793-16797 (October 23, 2007). The critical reagent, a substituted cyclooctyne, possesses ring strain and electron-withdrawing fluorine substituents that together promote a [3+ 2] dipolar cycloaddition with azides. See also,

US Pub. No. 2006/0110782 and Codelli et al., Second Generation Difluorinated Cyclooctynes for Copper-Free Click Chemistry, *J. Am. Chem. Soc.*, vol. 130, no. 34, 11486-11493 (2008). Another suitable cyclooctyne is 6,7-dimethoxyazacyclooct-4-yne (DIMAC). See, Sletton and Bertozzi, A hydrophilic azacyclooctyne for Cu-free click chemistry, *Org. Lett.* (2008) 10 (14), 3097-3099. Other click chemistry reactions include Diels-Alder reactions, thiol-alkene reactions, and maleimide-thiol reactions.

It would be advantageous to be able to secure medical gels via selective attachment at target sites within the body to prevent migration of the hydrogel without interfering with other hydrogel properties such as durability and the ability to be generally non-adherent when or where desired.

The present invention relates to a kit comprising :

- a medical gel having a plurality of reactive members of a specific binding pair adapted to be attached on a surface of the gel; and
- a container containing a mixture including complementary reactive members of the specific binding pair, the complementary reactive members having a functionality that will adhere them to biological tissue upon contact, said reactive members being capable of forming covalent bonds with the complementary reactive members of the specific binding pair via a click chemistry reaction.

By “reactive member” and “complementary reactive member” is meant, according to the present application, two compounds, also called a “specific binding pair” according to the present application, capable of reacting one with another, in particular by forming covalent bonds, according to a click chemistry reaction.

In embodiments, the members of the specific binding pair are intended to bind to one another via a reaction selected from the group consisting of Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction. For example, the members of the specific binding pair are alkynes and azides. In embodiments, the reactive member is an alkyne and the complementary reactive member is an azide. In alternative embodiments, the reactive member is an azide and the complementary reactive member is an alkyne.

In embodiments, the kit further comprises a metal catalyst to activate an alkyne and an azide for [3 + 2] cycloaddition reaction.

In embodiments, the alkyne is a cyclooctyne reagent, the reaction involves a cyclooctyne reagent and an azide for [3 + 2] cycloaddition.

In other embodiments, the members of the specific binding pair are thiols and alkenes

In other embodiments, the members of the specific binding pair are dienes and alkenes.

The tissue may be provided with complementary reactive members of the specific binding pair by applying a mixture or an aerosol containing the complementary reactive members to the tissue, the complementary reactive members being conjugated to a linker adapted to link the complementary reactive members to the tissue.

In embodiments, the complementary reactive members are conjugated to a linker adapted to link the complementary reactive members to the tissue. In embodiments, the linker is an RGD linker.

In embodiments, the linker is a ligand-receptor linkage.

In embodiments, the linker is selected from the group consisting of antibody, Fab, F(ab')₂, Fv, single chain antibody (SCA) and single complementary-determining region (CDR).

In embodiments, the linker is degradable by hydrolysis or enzymatic action.

5 In embodiments, the receptor of the ligand-receptor linkage is selected from the group consisting of peptides, oligosaccharides, oligonucleotides and lipids.

In embodiments, the medical gel is made of a polymer selected from the group consisting of polysaccharides, mucopolysaccharides, polyaminoacids, proteins, collagen-hydroxyethyl-methacrylate (HEMA), polyphosphazines, polyphosphoesters, polyethylene glycol, polyethylene oxide, polyvinyl alcohol, polyvinylpyrrolidone, polyethyloxazoline, 10 polyethylene oxide-co-polypropyleneoxide block copolymers, PGA-PEG-PGA block copolymers, PGA-PEG diblock copolymers, acrylates, PEG-oligoglycolylacrylates, polyacrylonitriles (PAN), carboxy alkyl celluloses, poly(α -hydroxy) acids, polylactones, polycaprolactones, polyanhydrides, polyorthoesters, polydioxanone, styrene, acrolein and 15 copolymers, block copolymers, homopolymers, blends and combinations thereof.

For example, the mucopolysaccharides are selected from the group consisting of hyaluronic acid, dextran, heparin sulfate, chondroitin sulfate, heparin, agar, starch, and alginate; the proteins are selected from the group consisting of fibronectin, gelatin, collagen, fibrin, pectins, albumin, ovalbumin, and polyamino acids; the acrylates are 20 selected from the group consisting of diacrylates, oligoacrylates, methacrylates, dimethacrylates and oligomethoacrylates; the carboxy alkyl celluloses are selected from the group consisting of carboxymethyl cellulose and partially oxidized cellulose; poly(α -hydroxy) acids selected from the group consisting of polyglycolic acid, poly-DL-lactic,

poly-L-lactic acid, and terpolymers of DL-lactide and glycolide; and polylactones selected from the group consisting of poly(ϵ -caprolactone), poly(δ -valerolactone) and poly(γ -butyrolactone), ϵ -caprolactone copolymerized with polyesters.

In embodiments, the mixture is a solution or a suspension of the complementary
5 reactive members of the specific binding pair.

In embodiments, the kit further comprises at least one applicator adapted to deliver the medical gel or the mixture to biological tissue.

The present invention further relates to a bioadherent substrate comprising a medical gel having a plurality of reactive members of a specific binding pair adapted to
10 be attached on a surface of the medical gel, said reactive members being capable of forming covalent bonds with a plurality of complementary reactive members of the specific binding pair via a click chemistry reaction. In embodiments, the click chemistry reaction is selected from the group consisting of Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction. In embodiments, the medical gel is a hydrogel. In
15 embodiments, the members of the specific binding pair are alkynes and azides.

In embodiments, the reaction is catalyzed by copper to activate an alkyne and an azide for [3 + 2] cycloaddition. For example, the reaction involves a cyclooctyne reagent and an azide for [3 + 2] cycloaddition.

In embodiments, the members of the specific binding pair are thiols and alkenes.

20 In other embodiments, the members of the specific binding pair are dienes and alkenes.

In embodiments, the medical gel is made of a polymer selected from the group consisting of polysaccharides, mucopolysaccharides, polyaminoacids, proteins, collagen-hydroxyethyl-methacrylate (HEMA), polyphosphazines, polyphosphoesters, polyethylene

glycol, polyethylene oxide, polyvinyl alcohol, polyvinylpyrrolidone, polyethyloxazoline, polyethylene oxide-co-polypropyleneoxide block copolymers, PGA-PEG-PGA block copolymers, PGA-PEG diblock copolymers, acrylates, PEG-oligoglycolylacrylates, polyacrylonitriles (PAN), carboxy alkyl celluloses, poly(α -hydroxy) acids, polylactones, polycaprolactones, polyanhydrides, polyorthoesters, polydioxanone, styrene, acrolein and copolymers, block copolymers, homopolymers, blends and combinations thereof.

The present invention further relates to a method of forming a medical gel having a selectively adhesive surface comprising:

providing a polymer capable of forming a gel, for example a hydrogel; and
functionalizing the polymer by attaching a plurality of reactive members of a specific binding pair to the polymer, said reactive members being capable of forming covalent bonds with a plurality of complementary reactive members of the specific binding pair via a click chemistry reaction.

In embodiments, the reaction is selected from the group consisting of Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction. In embodiments, the members of the specific binding pair are alkynes and azides. In embodiments, the reaction is catalyzed by copper to activate an alkyne and an azide for [3 + 2] cycloaddition. In embodiments, the reaction involves a cyclooctyne reagent and an azide for [3 + 2] cycloaddition.

In embodiments, the members of the specific binding pair are thiols and alkenes. In embodiments, the members of the specific binding pair are dienes and alkenes.

In embodiments, the gel being a hydrogel, the hydrogel is made of a polymer selected from the group consisting of polysaccharides, mucopolysaccharides,

polyaminoacids, proteins, collagen-hydroxyethyl-methacrylate (HEMA),
polyphosphazines, polyphosphoesters, polyethylene glycol, polyethylene oxide, polyvinyl
alcohol, polyvinylpyrrolidone, polyethyloxazoline, polyethylene oxide-co-
polypropyleneoxide block copolymers, PGA-PEG-PGA block copolymers, PGA-PEG
5 diblock copolymers, acrylates, PEG-oligoglycolylacrylates, polyacrylonitriles (PAN),
carboxy alkyl celluloses, poly(α -hydroxy) acids, polylactones, polycaprolactones,
polyanhydrides, polyorthoesters, polydioxanone, styrene, acrolein and copolymers, block
copolymers, homopolymers, blends and combinations thereof.

A method for adhering a medical gel to biological tissue is provided which
10 includes providing a medical gel having a plurality of reactive members of a specific
binding pair attached on to a medical gel or to precursor molecules of the medical gel,
and providing tissue with a plurality of complementary reactive members of the specific
binding pair, wherein upon contact of the reactive members of the medical gel with the
complimentary reactive members on the tissue, covalent bonds are formed between the
15 reactive members and the complementary reactive members, thus adhering the medical
gel to the tissue.

A bioadherent substrate is provided which includes a medical gel having a
plurality of reactive members of a specific binding pair attached thereto, said reactive
members being capable of forming covalent bonds with a plurality of complementary
20 reactive members of the specific binding pair via a reaction selected from a Huisgen
cycloaddition, a Diels-Alder reaction, a thiol-alkene reaction.

A kit is provided which includes a functionalized medical gel or medical gel
precursor molecules having a plurality of reactive members of a specific binding pair

adapted to be attached to the gel or medical gel precursor molecules; a container containing a solution or suspension of complementary reactive members of the specific binding pair, the complementary reactive members having a functionality that will adhere them to biological tissue upon contact; and at least one applicator adapted to deliver the

5 functionalized medical gel or medical gel precursors or the solution or suspension to biological tissue.

The invention further relates to a method for adhering a medical gel to biological tissue comprising:

providing a medical gel having a plurality of reactive members of a specific

10 binding pair attached to the medical gel; and

providing tissue with a plurality of complementary reactive members of the specific binding pair, wherein upon contact of the reactive members of the medical gel with the complimentary reactive members of the tissue, covalent bonds are formed between the reactive members and the complementary reactive members, thus adhering

15 the medical gel to the tissue.


DETAILED DESCRIPTION

A surgical adhesive system for medical gels and biological tissue is provided

20 which covalently bonds reactive members of a specific binding pair to one another via click chemistry. Click chemistry refers to a collection of reactive members having a high chemical potential energy capable of producing highly selective, high yield reactions. The reactive members react to form extremely reliable molecular connections in most solvents, including physiologic fluids, and often do not interfere with other reagents and

reactions. Examples of click chemistry reactions include Huisgen cycloaddition, Diels-Alder reactions, thiol-alkene reactions, and maleimide-thiol reactions.

Huisgen cycloaddition is the reaction of a dipolarophile with a 1,3-dipolar compound that leads to 5-membered (hetero)cycles. Examples of dipolarophiles are alkenes and alkynes and molecules that possess related heteroatom functional groups (such as carbonyls and nitriles). 1,3-Dipolar compounds contain one or more heteroatoms and can be described as having at least one mesomeric structure that represents a charged dipole. They include nitril oxides, azides, and diazoalkanes. Metal catalyzed click chemistry is an extremely efficient variant of the Huisgen 1,3-dipolar cycloaddition reaction between alkyl-aryl-sulfonyl azides, C-N triple bonds and C-C triple bonds which is well-suited herein. The results of these reactions are 1,2 oxazoles, 1,2,3 triazoles or tetrazoles. For example, 1,2,3 triazoles are formed by a copper catalyzed Huisgen reaction between alkynes and alkyl/aryl azides. Metal catalyzed Huisgen reactions proceed at ambient temperature, are not sensitive to solvents, i.e., nonpolar, polar, semipolar, and are highly tolerant of functional groups. Non-metal Huisgen reactions (also referred to as strain promoted cycloaddition) involving use of a substituted cyclooctyne, which possesses ring strain and electron-withdrawing substituents such as fluorine, that together promote a [3+ 2] dipolar cycloaddition with azides are especially well-suited for use herein due to low toxicity as compared to the metal catalyzed reactions. Examples include DIFO and DIMAC. Reaction of the alkynes and azides is very specific and essentially inert against the chemical environment of biological tissues. One reaction scheme may be represented as:




where R is a polymeric backbone and R' is a component of a biologic tissue.


Alternatively, R is a component of a biologic tissue and R' is a polymeric backbone.

The Diels-Alder reaction combines a diene (a molecule with two alternating
5 double bonds) and a dienophile (an alkene) to make rings and bicyclic compounds.

Examples include:



The thiol-alkene (thiol-ene) reaction is a hydrothiolation, i.e., addition of RS-H
10 across a C=C bond. The thiol-ene reaction proceeds via a free-radical chain mechanism. Initiation occurs by radical formation upon UV excitation of a photoinitiator or the thiol itself. Thiol-ene systems form ground state charge transfer complexes and therefore photopolymerize even in the absence of initiators in reasonable polymerization times. However, the addition of UV light increases the speed at which the reaction proceeds.
15 The wavelength of the light can be modulated as needed, depending upon the size and nature of the constituents attached to the thiol or alkene. A general thiol-ene coupling reaction mechanism is represented below:



In accordance with the disclosure herein, a medical gel, such as a hydrogel, is provided with a plurality of reactive members of a specific binding pair attached on the surface of the gel or to precursor molecules which form the gel. In the present

5 application, the term “gel” is meant to include gels in a gelified state and gel precursors such as uncured liquids intended to form gels after gelification. As used herein, unless otherwise specified, “attached to the surface of the gel” or “attached on the surface of the gel” or “located on the gel” is intended to include attachment to molecules which are precursors of the gel. As used herein “functionalized gel” means the gel provided with a

10 plurality of reactive members of a specific binding pair attached on the surface of the gel

A container containing a mixture including complementary reactive members of the specific binding pair, the complementary reactive members having a functionality adapted to adhere them to biological tissue upon contact, is further provided, forming a kit with the medical gel. The complementary reactive members are intended to be

15 adhered to the biological tissue via their functionality. When the reactive members of the

medical gel are contacted with biological tissue containing complementary reactive members of the specific binding pair, covalent attachment occurs, thus adhering the gel to the tissue. In embodiments, the reactive members may be either a dipolarophile or a 1,3 dipolar compound depending on which complement is applied to the target tissue or the

5 medical gel. For example, if a dipolarophile, as reactive member, is located on the gel, the 1,3 dipolar compound, as complementary reactive member, will be present in the mixture of the container, and thus further located on the tissue. If a dipolarophile, as complementary reactive member, is present in the mixture of the container, and thus further located on the tissue, the 1,3 dipolar compound, as reactive member, will be

10 located on the gel. In embodiments, the Diels-Alder members of a specific binding pair may be either a diene and a dienophile depending on which complement is applied to the target tissue or the medical gel. For example, if a diene is located on the gel, as reactive member, the dienophile, as complementary reactive member, can be present in the mixture of the container, and thus further located on the tissue. If a diene, as

15 complementary reactive member, is present in the mixture of the container, and further located on the tissue, the dienophile, as reactive member, can be located on the gel. In embodiments, the thiol-ene members of a specific binding pair may be either a thiol and an alkene depending on which complement is applied to the target tissue or the gel. For example, if a thiol, as reactive member, is located on the gel, the alkene, as

20 complementary reactive member, can be present in the mixture of the container, and further located on the tissue. If a thiol, as complementary reactive member, is present in the mixture of the container, and thus further located on the tissue, the alkene, as reactive member, can be located on the gel.

The medical gel may be biocompatible and bioabsorbable or biocompatible and non-bioabsorbable. In one embodiment, the reactive members are attached directly to the polymeric backbone of the gel. In another embodiment, the reactive members are attached to the polymeric backbone of the gel via a cross-linker. Cross-linkers are discussed below. Hydrogels can be formed, e.g., when an organic polymer, also referred to herein as precursor molecules which form the gel, which can be natural or synthetic, is set or at least partially solidified to create a three-dimensional open-lattice structure that entraps molecules of water or other solutions to form a gel. Hydrogels have an affinity for water and typically swell in water, but do not necessarily dissolve in water. Solidification can occur by aggregation, coagulation, hydrophobic interactions, cross-linking, or similar means. In certain embodiments, hydrogels are formed by polymerization and crosslinking of a hydrophilic monomer in an aqueous solution to cause the solution to gel. In 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000

embodiments, the hydrogel is composed of 85% water, to which can be added any salt or adjuvant.

Hydrogels may be organic gels or inorganic gels. Organic gels from which the hydrogel of the invention can be selected include, by way of example and not by way of limitation, gels formed from polysaccharides and mucopolysaccharides including, but not limited to hyaluronic acid, dextran, heparin sulfate, chondroitin sulfate, agar, starch, and alginate; proteins, including but not limited to, fibronectin, gelatin, collagen, fibrin, chitosan, chitin, pectins, albumin, ovalbumin, and polyamino acids; collagen-hydroxyethyl-methacrylate (HEMA); polyphosphazines; polyphosphoesters; polyethylene glycol; polyethylene oxide; polyvinyl alcohol; polyvinylpyrrolidone; polyethyloxazoline; polyethylene oxide-co-polypropyleneoxide block copolymers; PGA

(polyglycolic acid)-PEG (polyethylene glycol)-PGA block copolymers; PGA-PEG diblock copolymers; acrylates, including but not limited to diacrylates, oligoacrylates, methacrylates, dimethacrylates and oligomethacrylates; PEG-oligoglycolylacrylates; polyacrylonitriles (PAN); carboxy alkyl celluloses, including but not limited to

5 carboxymethyl cellulose; partially oxidized cellulose; biodegradable polymers including but not limited to polymers and oligomers of glycolide, lactide, polyesters of α -hydroxy acids, including lactic acid and glycolic acid, such as the poly(α -hydroxy) acids including polyglycolic acid, poly-DL-lactic acid, poly-L-lactic acid, and terpolymers of DL-lactide and glycolide; ϵ -caprolactone and ϵ -caprolactone copolymerized with

10 polyesters; polylactones and polycaprolactones including poly(ϵ -caprolactone), poly(δ -valerolactone) and poly(γ -butyrolactone); polyanhydrides; polyorthoesters; polydioxanone; and other biologically degradable polymers that are non-toxic or are present as metabolites in the body; as well as non-degradable polymers such as styrene and acrolein.

15 Collagen-hydroxyethyl-methacrylate (EMA) hydrogel polymer is commonly formed from a gelled and crosslinked hydrophilic monomer solution to form a three dimensional polymeric meshwork anchoring macromolecules. Crosslinking of the hydrophilic monomer solution can be accomplished by free radical polymerization of hydrophilic monomers, such as hydroxyethyl-methacrylate (HEMA). Hydrogel polymers

20 formed by free radical polymerization of monomer solutions require crosslinking to form the three dimensional network to gel the aqueous solution. HEMA monomer solutions typically can be crosslinked to gel by dimethacrylate, although other crosslinking agents, such as ethylene glycol dimethacrylate or methylmethacrylate, can also be used during

polymerization to modify the hydrogel. A wide variety of other hydrophilic monomers may also be suitable for purposes of the invention. Inorganic gels include, by way of example and not by way of limitation, silica, alumina, and ferric oxide.

Bulk and cellular hydrogels may be prepared by covalent cross linking or physical
5 cross linking of the hydrogel molecules. Thus, covalent cross linking, also known as chemical cross linking, includes the use of multi-functional reactive chemical molecules such as aldehydes, maleic acid, dimethyl urea, di-isocyanates, boric acid, and the like, and also the use of ionizing radiation, ultraviolet light, and the like, while physical cross linking methods, also known as reversible cross linking, includes cross linking through
10 crystallites, hydrogen bonding and complexing agents such as titanium, aluminum, manganese, and copper, to name a few. Physical cross linking through formation of crystallites in, e.g., polyvinyl alcohols, chitosan and the like, using, for example, partial freeze-drying, repeated freezing and thawing, low temperature crystallization, physical cross linking induced by the presence of aqueous solutions of organic compounds, salts,
15 acids and bases and the like.

In the present application, the terms "biodegradable", "bioresorbable" and "bioabsorbable" are used interchangeably and are intended to mean the characteristic according to which a gel and/or a material is resorbed by the biological tissues and the surrounding fluids and disappears in vivo after a given period of time, that may vary, for
20 example, from one day to several months, depending on the chemical nature of the implant and/or of the material. Non bioresorbable material - also called permanent material - is not substantially resorbed by tissues and surrounding fluids, after 2 years and more, keeping in particular most (e.g., > 80 %) of their mechanical properties after such a time. The term

"biocompatible" is intended to mean the characteristic according to which a gel and/or a material is well integrated by the biological tissues and the surrounding fluids without inducing excessive inflammation reaction around the bulk of the material or due to its degradation. The material should avoid also the formation of a fibrous capsule which usually results in the delay of the cellular integration of a porous implant.

Many of the above described examples of polymers do not contain functional groups, in other words reactive members, in their molecules. In embodiments, the reactive members are attached to the medical gel by surface modification techniques such as plasma treatment, silane coupling treatment and acid sensitization. Surface activation of the medical gel can be achieved by acid or base hydrolysis, treatment by means of cold plasma, by chemical reactions or electromagnetic radiations.

Hydrolysis can be conducted in the presence of an aqueous solution of a base or an acid to accelerate surface reaction, inasmuch as excessively long processes of activation can induce a reduction in molecular weight and thus in the mechanical properties of the material. Suitable bases for obtaining watery solutions suited to the aim are, for example, strong alkalis, such as LiOH, Ba(OH)₂, Mg(OH)₂, NaOH, KOH, Na₂CO₃, Ca(OH)₂ and the weak bases, such as for example NH₄ OH and the amines such as methylamine, ethylamine, diethylamine and dimethylamine. Acids suitable for surface hydrolysis treatments can be chosen, for example, from among HCl, HClO₃, HClO₄, H₂SO₃, H₂SO₄, H₃PO₃, H₃PO₄, HI, HIO₃, HBr, lactic acid, glycolic acid. Surface activation by means of hydrolysis can be conducted at temperatures preferably comprised between 0 degrees Celsius and the material softening temperature.

Plasma treatment can be carried out both in the presence of a reactive gas, for example air, Ar, O₂ with the formation of surface activation of oxygenate type, such as –OH, –CHO, –COOH.

Surface treatment, whether hydrolytic or with plasma, can remain unaltered or can
5 be followed by further chemical modifications to provide the first reactive groups on the bioabsorbable or non bioabsorbable polymeric substrate. Thus, for example, the COONa groups generated by a base hydrolysis can be subsequently converted into COOH groups by treatment with strong mineral acids. Further, the surface freeing of alcoholic groups by means of a hydrolysis process can be followed by reaction by means of the addition of a
10 compound provided with functional group or groups able to react with surface alcoholic groups, such as for example by means of the addition of an anhydride such as succinic anhydride, with the conversion of –OH groups into –O–CO–CH₂–CH₂–COOH groups. Suitable surface activation techniques are disclosed in U.S. Patent No. 6,107,453, the entire disclosure of which is incorporated herein by this reference.

15 During manufacture of polymers intended to form the medical gel of the invention, pendant functional groups or reactive members can be incorporated into the polymer backbone by, e.g., copolymerization with functionalized monomer such as lactones, cyclic carbonates and morpholine-2, 5-diones. The azido group, N₃ is a nucleophilic group that will exchange with other nucleophilic groups, e.g., –OH, –NH₂
20 and halogens (Br, Cl, or I). For example, 1,3-dipolar compounds may be conjugated to aliphatic polyesters, by copolymerizing, e.g., ϵ -caprolactone and α -chloro- ϵ -caprolactone and then substituting an azide group for the Cl atom. Polyesters can incorporate pendant dipolarophiles, e.g., propargyl groups, by copolymerization of ϵ -caprolactone and α -

propargyl- δ -valerolactone. Copolymers of L-lactide containing propargyl groups may, e.g., be prepared by ring opening copolymerization of 5-methyl-5-propargyloxycarbonyl-1,3-dioxanone with L-lactide at a molar ratio of about 90:10 with ZnEt_2 as a catalyst. See, Shi et al., *Biomaterials*, 29 (2008)1118-1126. Azide functionalized polystyrene is

5 synthesized using atom transfer radical polymerization and subsequent modification with azidotrimethylsilane and tetrabutylammonium fluoride. See, Dirks, et al., *Chem. Comm.*, (2005) 4172-4174. Azides may be incorporated onto methacrylates, e.g., 3 azidopropyl methacrylate which is copolymerized to a block copolymer. Diels-Alder functionalities and thiol-ene functionalities are likewise incorporated into polymers herein.

10 Biological tissue is provided with complementary reactive members of a specific binding pair, present in the mixture of the container of the kit of the invention, by conjugation to various components of tissue such as proteins, lipids, oligosaccharides, oligonucleotides, glycans, including glycosaminoglycans. In one embodiment, the complementary reactive members are attached directly to components of the tissue. In

15 another embodiment, the complementary reactive members are attached to components of the tissue via a linker. In either case, situating the complementary reactive members on the tissue can be accomplished by suspending the complementary reactive members of the mixture of the container of the kit of the invention in a solution or suspension and applying the solution or suspension to the tissue such that the complementary reactive

20 members binds to a target. The solution or suspension may be poured, sprayed or painted onto the tissue, whereupon the complementary reactive members are incorporated into the tissue.

1,3-Dipolar compounds can be incorporated into proteins, lipids, oligosaccharides, oligonucleotides and glycans using, e.g., metabolic machinery, covalent inhibitors and enzymatic transfers. For example, an azido group, N_3 , can be applied at the N-terminus of proteins or peptides using azidoacetyl chloride. See, e.g., Haridas, et al.,
5 Tetrahedron Letters 48 (2007) 4719-4722. The azido group is a nucleophilic group that will exchange with other nucleophilic groups, e.g., $-OH$, $-NH_2$ and halogens (Br, Cl, or I). NaN_3 is an azidizing agent which is capable of aziding proteins by simply contacting the proteins with a 10 times molar excess of NaN_3 . A process for C-terminal azidization is described in Cazalis, et al., Bioconjugate Chem., 15 (2004) 1005-1009. Incubation of
10 cells with peracetylated N-azidoacetylmannosamine provides cell surface glycans with azido sialic acid. See, e.g., Codelli et al., J. Amer. Chem. Soc., 130 (34) 11486-11493 (2008). Azido-tagged lipids are described in Smith, et al., Bioconjugate Chem., 19 (9), 1855-1863 (2008). PEGylation is a commonly used technique for adding groups to peptides and proteins and is suitable for use herein. For example, PEG may be covalently
15 bound to amino acid residues via a reactive group. Reactive groups (as opposed to reactive members and complementary reactive members herein) are those to which an activated PEG molecule may be bound (e.g., a free amino or carboxyl group). For example, N-terminal amino acid residues and lysine (K) residues have a free amino group and C-terminal amino acid residues have a free carboxyl group. Sulfhydryl groups (e.g.,
20 as found on cysteine residues) may also be used as a reactive group for attaching PEG. In addition, enzyme-assisted methods for introducing activated groups (e.g., hydrazide, aldehyde, and aromatic-amino groups) specifically at the C-terminus of a polypeptide may be used. Accordingly, PEG incorporating 1,3-dipolar compounds may be utilized

herein Those skilled in the art can utilize any known process for coupling a 1,3-dipolar compound into proteins, lipids, oligosaccharides, oligonucleotides and glycans.

Dipolarophile functionalized proteins and peptides can be synthesized by linking at the N-terminus with, for example, an alkyne (e.g., 3 butynyl chloroformate), in
5 connection with a tripeptide (GlyGlyArg). See, Dirks, et al., *supra*. A suitable tripeptide herein is the well-known cell adhesion sequence RGD (Arginine-Glycine-Aspartic acid). It should be understood that, as used herein, "proteins" is intended to encompass peptides and polypeptides. In one embodiment, thiols on cysteines are functionalized with alkyne bearing maleimide. *Id.* Providing a C-terminal dipolarophile can be accomplished, e.g.,
10 by coupling with propargylamine using a cross-linking agent such as N-hydroxysuccinimide/DCC. See, e.g., Haridas, et al. *supra*. Terminal alkynes can be installed using metabolic building blocks such as alkynoic acids. Lipids may be functionalized with alkynes. For example, alkyne modified fatty acids can be generated by reaction of terminal alkynyl-alkyl bromide with trimethyl phosphine to yield a 16-
15 carbon alkynyl-dimethylphosphonate. See, e.g., Raghavan et al., *Bioorg. Med. Chem. Lett.*, 18 (2008) 5982-5986. As above, PEGylation may be used for adding dipolarophile groups to peptides and proteins and is suitable for use herein. Diels-Alder functionalities and thiol-ene functionalities are likewise attached to proteins, lipids, oligosaccharides, oligonucleotides and glycans.

20 The complementary reactive members may be also attached to biological tissue or the medical gel via a linker. In such a case, the complementary reactive members present in the mixture of the container of the kit of the invention are conjugated to the linker. In certain embodiments, the linker is or includes a ligand which bears a complementary

reactive member. The ligand binds to a desired target on the tissue and thus provides a vehicle for transporting and indirectly binding the complementary reactive member to the tissue. The ligand herein is any molecule or combination of molecules which demonstrates an affinity for a target. Examples of ligands include nucleic acid probes, antibodies, hapten conjugates, and cell adhesion peptides such as RGD. The mechanisms involved in obtaining and using such ligands are well-known. In embodiments, complementary reactive members are incorporated into saccharides or polysaccharides and metabolically incorporated into cells. See, e.g., Baskin et al., *supra*.

Antibodies that specifically recognize antigens are useful in accordance with one embodiment herein. Antibodies which are conjugated to a complementary reactive member are utilized to bind to proteins located on tissue. Monoclonal or polyclonal antibodies are raised against an antigen which can be any component of biological tissue and then purified using conventional techniques. The term "antibody" is intended to include whole antibodies, e.g., of any isotype (IgG, IgA, IgM, IgE, etc.), and to include fragments thereof which are also specifically reactive with a vertebrate, e.g., mammalian, protein. Antibodies may be fragmented using conventional techniques and the fragments screened for utility in the same manner as for whole antibodies. Thus, the term includes segments of proteolytically-cleaved or recombinantly-prepared portions of an antibody molecule that are capable of selectively reacting with a certain protein. Non-limiting examples of such proteolytic and/or recombinant fragments include Fab, F(ab')₂, Fab', Fv, and single chain antibodies (scFv) containing a V[L] and/or V[H] domain joined by a peptide linker. The scFv's may be covalently or non-covalently linked to form antibodies

having two or more binding sites. The present disclosure includes polyclonal, monoclonal or other purified preparations of antibodies and recombinant antibodies.

After purification, the ligands (e.g., antibodies, nucleic acid probes, hapten conjugates and cell adhesion peptides), are conjugated or linked to complementary reactive members in the manners described above. In addition, complementary reactive members can be linked to ligands by cross-linking procedures which, in accordance with the present invention, do not cause denaturing or misfolding of the ligands. The terms "linked" or "conjugated" as used herein are used interchangeably and are intended to include any or all of the mechanisms known in the art for coupling the complementary reactive members to the ligand. For example, any chemical or enzymatic linkage known to those with skill in the art is contemplated including those which result from photoactivation and the like. Homofunctional and heterobifunctional cross linkers are all suitable. Reactive groups (distinguishable from reactive members or complementary reactive members herein) which can be cross-linked with a cross-linker include primary amines, sulfhydryls, carbonyls, carbohydrates and carboxylic acids.

Cross-linkers are conventionally available with varying lengths of spacer arms or bridges. Cross-linkers suitable for reacting with primary amines include homobifunctional cross-linkers such as imidoesters and N-hydroxysuccinimidyl (NHS) esters. Examples of imidoester cross-linkers include dimethyladipimidate, dimethylpimelimidate, and dimethylsuberimidate. Examples of NHS-ester cross-linkers include disuccinimidyl glutamate, disuccinimidyl suberate and bis (sulfosuccinimidyl) suberate. Accessible amine groups present on the N-termini of peptides react with NHS-esters to form amides. NHS-ester cross-linking reactions can be conducted in phosphate,

bicarbonate/carbonate, HEPES (2-[4-(2-hydroxyethyl)piperazin-1-yl]) and borate buffers. Other buffers can be used if they do not contain primary amines. The reaction of NHS-esters with primary amines should be conducted at a pH of between about 7 and about 9 and a temperature between about 4°C and 30°C for about 30 minutes to about 2 hours.

5 The concentration of NHS-ester cross-linker can vary from about 0.1 to about 10 mM. NHS-esters are either hydrophilic or hydrophobic. Hydrophilic NHS-esters are reacted in aqueous solutions although DMSO (dimethylsulfoxide) may be included to achieve greater solubility. Hydrophobic NHS-esters are dissolved in a water miscible organic solvent and then added to the aqueous reaction mixture.

10 Sulfhydryl reactive cross-linkers include maleimides, alkyl halides, aryl halides and α -haloacetyls which react with sulfhydryls to form thioether bonds and pyridyl disulfides which react with sulfhydryls to produce mixed disulfides. Sulfhydryl groups on peptides and proteins can be generated by techniques known to those with skill in the art, e.g., by reduction of disulfide bonds or addition by reaction with primary amines using 2-
15 iminothiolane. Examples of maleimide cross-linkers include succinimidyl 4-(N-maleimido-methyl) cyclohexane-1-carboxylate and m-maleimidobenzoyl-N-hydroxysuccinimide ester. Examples of haloacetal cross-linkers include N-succinimidyl (4-iodoacetal) aminobenzoate and sulfosuccinimidyl (4-iodoacetal) aminobenzoate. Examples of pyridyl disulfide cross-linkers include 1,4-Di-[3'-2'-
20 pyridyldithio(propionamido)butane] and N-succinimidyl-3-(2-pyridyldithio)-propionate.

Carboxyl groups are cross-linked to primary amines or hydrazides by using carbodimides which result in formation of amide or hydrazone bonds. In this manner, carboxy-termini of peptides or proteins can be linked. Examples of carbodiimide cross-

linkers include 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride and N, N¹-dicyclohexylcarbodiimide. Arylazide cross-linkers become reactive when exposed to ultraviolet radiation and form aryl nitrene. Examples of arylazide cross-linkers include azidobenzoyl hydrazide and N-5-azido-2 nitrobenzoyloxysuccinimide. Glyoxal cross
5 linkers target the guanidyl portion of arginine. An example of a glyoxal cross-linker is p-azidophenyl glyoxal monohydrate.

Heterobifunctional cross-linkers which possess two or more different reactive groups are suitable for use herein. Examples include cross-linkers which are amine-reactive at one end and sulfhydryl-reactive at the other end such as 4-succinimidyl-
10 oxycarbonyl-a-(2-pyridyldithio)-toluene, N-succinimidyl-3-(2-pyridyldithio)-propionate and the maleimide cross-linkers discussed above.

Attachment of reactive members to the surface of the medical gel of the invention functionalizes the gel such that upon exposure to their complementary reactive members which are situated on tissue, they are activated and form a covalent bond, thus adhering
15 the gel to the tissue. In one embodiment, a linker between the product of the complementary reactive members and the biological tissue is degradable by, e.g., hydrolysis or enzymatic action. In this manner, the medical gel can be removable after a period of time. The degradable linkage may be chelates or chemically or enzymatically hydrolyzable or absorbable. Illustrative chemically hydrolyzable degradable linkages
20 include polymers, copolymers and oligomers of glycolide, dl-lactide, l-lactide, caprolactone, dioxanone, and tritnethylene carbonate. Illustrative enzymatically hydrolyzable biodegradable linkages include peptidic linkages cleavable by metalloproteinases and collagenases and chitosan cleavable by lysozyme. Additional

illustrative degradable linkages include polymers and copolymers of poly(hydroxy acid)s, poly(orthocarbonate)s, poly(anhydride)s, poly(lactone)s, poly(amino acid)s, poly(carbonate)s, poly(saccharide)s and poly(phosphonate)s. In certain embodiments, the degradable linkage may contain ester linkages. Some non-limiting examples include
5 esters of succinic acid, glutaric acid, propionic acid, adipic acid, or amino acids, as well as carboxymethyl esters.

The ligand solution and gel can be sterilized by any known method, e.g., irradiation, ethylene oxide, filtration in sterile conditions on a 0.22um filter and the like.

Medical gels herein may be used in a variety of applications. In one embodiment,
10 the gel is an uncured liquid, functionalized with a plurality of reactive members of a binding pair, which is applied and cured as a layer on surfaces of internal organs or tissues which were pretreated with the complementary reactive member as described above. The target tissue is pretreated by spraying, painting or pouring a solution or suspension containing the complementary reactive members of a binding pair on to the
15 tissue. Ligands associated with the complementary reactive members bind to their predetermined targets on the tissue, thereby anchoring the complementary reactive members on the tissue. The uncured functionalized liquid gel is sprayed over, e.g., a defect on the tissue where it cures while simultaneously, the reactive members and complementary reactive members of the specific binding pair react specifically together
20 to form covalent bonds, providing adhesion between the tissue and the curing or cured gel. In another embodiment, the functionalized gel is cured prior to application to pretreated tissue and then draped over or otherwise contacted with the target or defect to allow the covalent bond forming reaction to occur with consequent covalent bonding and

adherence. In certain embodiments, two opposing tissue surfaces are pretreated and functionalized (i.e. are provided with complementary reactive members as described above), and the functionalized gel added to form bonds to both opposing tissue surfaces.

Some applications include using the medical gel composition to bind tissue
5 together either as an adjunct to or as a replacement of sutures, staples, tapes and/or bandages. In another application, the present gels may be used to prevent post-surgical adhesions. In this application, the gel, functionalized with a reactive member of a binding pair, is applied and cured as a layer on surfaces of internal organs or tissues which were pretreated with a complementary reactive member of the binding pair as described above
10 in order to prevent the formation of adhesions at a surgical site as the site heals. In another application, the functionalized gel may be used to attach pretreated skin grafts and to position pretreated tissue flaps or free flaps during reconstructive surgery. In still another application, the functionalized gel of the invention may be used to close pretreated gingival flaps in periodontal surgery. Additional applications of the
15 functionalized gel of the invention include sealing tissues to prevent or control blood or other fluid leaks at suture or staple lines as well as to prevent or control air leaks in the pulmonary system.

In addition, functionalized medical gels herein can be used as bulking agents, e.g., they can be injected via a syringe and needle or other generally accepted means directly
20 into a specific area wherever a bulking agent is desired, i.e., a pretreated soft tissue deformity such as that seen with areas of muscle atrophy due to congenital or acquired diseases or secondary to trauma, burns, and the like. An example of this would be the injection of a medical gel herein in the upper torso of a patient with muscular atrophy

secondary to nerve damage. A medical gel herein can also be injected as a bulking agent for hard tissue defects, such as bone or cartilage defects, either congenital or acquired disease states, or secondary to trauma, burns, or the like. An example of this would be an injection into the area surrounding the skull where a bony deformity exists secondary to
5 trauma. The injection in these instances can be made directly into the needed area with the use of a needle and syringe under local or general anesthesia.

A medical gel of the invention could also be injected percutaneously by direct palpation, such as by placing a needle inside a pretreated vas deferens and occluding the same with the injected functionalized bulking medical gel, thus rendering the patient infertile. The
10 gel could also be injected through a catheter or needle with fluoroscopic, sonographic, computed tomography, magnetic resonance imaging or other type of radiologic guidance. This would allow for placement or injection of the pretreatment formulation and subsequent functionalized medical gel either by vascular access or percutaneous access to specific organs or other tissue regions in the body, wherever a bulking agent would be
15 required.

Techniques of tissue engineering employing functionalized medical gel scaffolds can be used to create alternatives to prosthetic materials currently used in craniomaxillofacial surgery, as well as formation of organ equivalents to replace diseased, defective, or injured tissues. Medical gels herein can be malleable and used to
20 encapsulate cells. To form a hydrogel containing the cells, a functionalized polymer solution is mixed with the cells to be implanted to form a suspension. Then, in one embodiment, the target site is pretreated with complementary members of a specific binding pair and the functionalized polymers in suspension are injected directly into a

patient prior to crosslinking of the polymer to form the hydrogel containing the cells. The hydrogel cures over a short period of time while simultaneously binding to the pretreated area through covalent bond formation. In another embodiment, the functionalized gel is injected or poured into a mold, where it crosslinks to form a semi-solid hydrogel of the
5 desired anatomical shape having cells dispersed therein which then may be implanted in a pretreated target area in a patient. The hydrogel may be produced, for example, by crosslinking a polysaccharide polymer by exposure to a monovalent cation. Other polymers capable of forming functionalized hydrogels as described above may be used as disclosed herein. In the embodiments where the functionalized polymer is crosslinked by contact
10 with a crosslinking agent, the strength of the crosslink may be increased or reduced by adjusting the concentration of the polymer and/or crosslinking agent.

Further, combinations in accordance with this disclosure, e.g., functionalized medical gel having reactive members of a specific binding pair and functionalized pretreatment formulation or mixtures containing complementary reactive members of the
15 specific binding pair, could be injected through a laparoscope or thoracoscope to any intraperitoneal or extraperitoneal or thoracic organ. For example, the functionalized pretreatment formulation or mixtures and functionalized gel could be injected in the region of the gastroesophageal junction for the correcting of gastroesophageal reflux. This could be performed either with a thoracoscope injecting the substances in the
20 esophageal portion of the gastroesophageal region, or via a laparoscope by injecting the substances in the gastric portion of the gastroesophageal region, or by a combined approach.

A kit for a functionalized adhesive herein includes a medical gel which has a plurality of reactive members of a specific binding pair adapted to be attached to a surface of the gel and an applicator adapted to contain a solution or suspension of complementary reactive members of the specific binding pair, the complementary reactive members having a functionality that will adhere them to biological tissue upon contact. The kit may optionally include a container which contains a catalyst for causing the reactive members of a specific binding pair to bind with the complementary reactive members of the specific binding pair. The catalyst may be a solution of metal such as copper. In embodiments, the kit contains a microwave or ultraviolet radiation generator.

It should be understood that variations can be made to the above embodiments that are within the purview of ordinary skill in the art. For example, other click chemistry reactions are suitable for use herein, e.g., Staudinger reaction of phosphines with alkyl azides. Accordingly, those skilled in the art can envision modifications which are included within the scope of the claimed invention that are not expressly set forth herein.

WHAT IS CLAIMED IS:

1. A kit comprising:

- 5 - a medical gel having a plurality of reactive members of a specific binding pair adapted to be attached on a surface of the gel; and
- a container containing a mixture including complementary reactive members of the specific binding pair, the complementary reactive members having a functionality that will adhere them to biological tissue upon contact,
- 10 said reactive members being capable of forming covalent bonds with the complementary reactive members of the specific binding pair via a click chemistry reaction.
2. The kit according to claim 1 wherein the members of the specific binding pair are intended to bind to one another via a reaction selected from the group consisting of
- 15 Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction.
3. The kit according to claim 1 or 2 wherein the members of the specific binding pair are alkynes and azides.
- 20 4. The kit according to any one of claims 1 to 3 wherein the reactive member is an alkyne and the complementary reactive member is an azide.
5. The kit according to any one of claims 1 to 3 wherein the reactive member is an azide and the complementary reactive member is an alkyne.

6. The kit according to any one of claims 2 to 5 wherein kit further comprises a metal catalyst to activate an alkyne and an azide for [3 + 2] cycloaddition reaction.
- 5 7. The kit according to any one of claims 3 to 6 wherein the alkyne is a cyclooctyne reagent, the reaction involving a cyclooctyne reagent and an azide for [3 + 2] cycloaddition.
8. The kit according to claim 1 or 2 wherein the members of the specific binding pair are
10 thiols and alkenes
9. The kit according to claim 1 or 2 wherein the members of the specific binding pair are dienes and alkenes.
- 15 10. The kit according to any one of claims 1 to 9 wherein the complementary reactive members are conjugated to a linker adapted to link the complementary reactive members to the tissue.
11. The kit according to claim 10 wherein the linker is an RGD linker.
- 20 12. The kit according to claim 10 wherein the linker is a ligand-receptor linkage.

13. The kit according to claim 12 wherein the a linker is selected from the group consisting of antibody, Fab, F(ab')₂, Fv, single chain antibody (SCA) and single complementary-determining region (CDR).
- 5 14. The kit according to claim 10 wherein the linker is degradable by hydrolysis or enzymatic action.
15. The kit according to claim 12 wherein the receptor of the ligand-receptor linkage is selected from the group consisting of peptides, oligosaccharides, oligonucleotides and
10 lipids.
16. The kit according to any one of claims 1 to 15 wherein the medical gel is made of a polymer selected from the group consisting of polysaccharides, mucopolysaccharides, polyaminoacids, proteins, collagen-hydroxyethyl-methacrylate (HEMA),
15 polyphosphazines, polyphosphoesters, polyethylene glycol, polyethylene oxide, polyvinyl alcohol, polyvinylpyrrolidone, polyethyloxazoline, polyethylene oxide-co-polypropyleneoxide block copolymers, PGA-PEG-PGA block copolymers, PGA-PEG diblock copolymers, acrylates, PEG-oligoglycolylacrylates, polyacrylonitriles (PAN), carboxy alkyl celluloses, poly(α -hydroxy) acids, polylactones, polycaprolactones,
20 polyanhydrides, polyorthoesters, polydioxanone, styrene, acrolein and copolymers, block copolymers, homopolymers, blends and combinations thereof.

17. The kit according to claim 16 wherein the mucopolysacharrides are selected from the group consisting of hyaluronic acid, dextran, heparin sulfate, chondroitin sulfate, heparin, agar, starch, and alginate; the proteins are selected from the group consisting of fibronectin, gelatin, collagen, fibrin, pectins, albumin, ovalbumin, and polyamino acids;

5 the acrylates are selected from the group consisting of diacrylates, oligoacrylates, methacrylates, dimethacrylates and oligomethoacrylates; the carboxy alkyl celluloses are selected from the group consisting of carboxymethyl cellulose and partially oxidized cellulose; poly(α -hydroxy) acids selected from the group consisting of polyglycolic acid, poly-DL-lactic, poly-L-lactic acid, and terpolymers of DL-lactide and glycolide; and

10 polylactones selected from the group consisting of poly(ϵ -caprolactone), poly(δ -valerolactone) and poly(γ -butyrolactone), ϵ -caprolactone copolymerized with polyesters.

18. The kit according to any one of claims 1 to 17, wherein the mixture is a solution or a suspension of the complementary reactive members of the specific binding pair.

15

19. The kit according to any one of claims 1 to 18 wherein and the kit further comprises at least one applicator adapted to deliver the medical gel or the mixture to biological tissue.

20 20. A bioadherent substrate comprising a medical gel having a plurality of reactive members of a specific binding pair adapted to be attached on a surface of the medical gel, said reactive members being capable of forming covalent bonds with a plurality of

complementary reactive members of the specific binding pair via a click chemistry reaction.

21. A bioadherent substrate according to claim 20, wherein the click chemistry reaction is
5 selected from the group consisting of Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction.
22. The bioadherent substrate according to claim 20 or 21 wherein the medical gel is a
hydrogel.
10
23. The bioadherent substrate according to any one of claims 20 to 22 wherein the members of the specific binding pair are alkynes and azides.
24. The bioadherent substrate according to claim 21 wherein the reaction is catalyzed by
15 copper to activate an alkyne and an azide for [3 + 2] cycloaddition.
25. The bioadherent substrate according to claim 21 wherein the reaction involves a cyclooctyne reagent and an azide for [3 + 2] cycloaddition.
- 20 26. The bioadherent substrate according to claim 21 wherein the members of the specific binding pair are thiols and alkenes.

27. The bioadherent substrate according to claim 21 wherein the members of the specific binding pair are dienes and alkenes.

28. The bioadherent substrate according to any one of claims 21 to 27 wherein the
5 medical gel is made of a polymer selected from the group consisting of polysaccharides, mucopolysaccharides, polyaminoacids, proteins, collagen-hydroxyethyl-methacrylate (HEMA), polyphosphazines, polyphosphoesters, polyethylene glycol, polyethylene oxide, polyvinyl alcohol, polyvinylpyrrolidone, polyethyloxazoline, polyethylene oxide-co-
10 polypropyleneoxide block copolymers, PGA-PEG-PGA block copolymers, PGA-PEG diblock copolymers, acrylates, PEG-oligoglycolylacrylates, polyacrylonitriles (PAN), carboxy alkyl celluloses, poly(α -hydroxy) acids, polylactones, polycaprolactones, polyanhydrides, polyorthoesters, polydioxanone, styrene, acrolein and copolymers, block copolymers, homopolymers, blends and combinations thereof.

15 29. A method of forming a medical gel having a selectively adhesive surface comprising:
providing a polymer capable of forming a gel, for example a hydrogel; and
functionalizing the polymer by attaching a plurality of reactive members of a
specific binding pair to the polymer, said reactive members being capable of forming
covalent bonds with a plurality of complementary reactive members of the specific
20 binding pair via a click chemistry reaction.

30. The method according to claim 29, wherein the reaction is selected from the group consisting of Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction.

5 31. The method according to claim 29 or 30 wherein the members of the specific binding pair are alkynes and azides.

32. The method according to claim 29 or 30 wherein the reaction is catalyzed by copper to activate an alkyne and an azide for [3 + 2] cycloaddition.

10

33. The method according to any one of claims 29 to 32 wherein the reaction involves a cyclooctyne reagent and an azide for [3 + 2] cycloaddition.

15 34. The method according to claim 29 or 30 wherein the members of the specific binding pair are thiols and alkenes.

35. The method according to claim 29 or 30 wherein the members of the specific binding pair are dienes and alkenes.

20 36. The method according to any one of claims 29 to 35 wherein the gel being a hydrogel, the hydrogel is made of a polymer selected from the group consisting of polysaccharides, mucopolysaccharides, polyaminoacids, proteins, collagen-hydroxyethyl-methacrylate (HEMA), polyphosphazines, polyphosphoesters, polyethylene glycol,

polyethylene oxide, polyvinyl alcohol, polyvinylpyrrolidone, polyethyloxazoline,
polyethylene oxide-co-polypropyleneoxide block copolymers, PGA-PEG-PGA block
copolymers, PGA-PEG diblock copolymers, acrylates, PEG-oligoglycolylacrylates,
polyacrylonitriles (PAN), carboxy alkyl celluloses, poly(α -hydroxy) acids, polylactones,
5 polycaprolactones, polyanhydrides, polyorthoesters, polydioxanone, styrene, acrolein and
copolymers, block copolymers, homopolymers, blends and combinations thereof.